Phase 1 trials in VP-001 won’t happen before next year – at last reporting (14/01), IND submission was slated for H1 2022.
But there are a number of other inflection points in the nearer term.
For VP-001 (Retinitis Pigmentosa type 11), large animal toxicity results are due to be reported by mid-year.
For PYC-001 (Diabetic Retinopathy), efficacy readouts in patient-derived models are expected in this half.
For VP-002 (autosomal dominant optic atrophy), efficacy readouts in patient-derived models are also expected this half.
Potentially also in this half will be the identification of PYC’s fourth inherited retinal disease and first neurodegenerative disease pipeline candidates, once the relevant IP is filed (20/10). The neurodegenerative disease candidate is likely to address a much larger market than the IRD candidates and will possibly be developed in collaboration with another party.
PYC Price at posting:
14.0¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)